Using a chimeric T-cell receptor that binds to the 5T4 protein we have evaluated whether T cells from patients with RCC could be genetically modified to kill allogeneic 5T4-expressing renal cell lines. This evidence concerns the gene TPBG and renal cell adenocarcinoma.